Mirae Asset Global Investments
PEAR

Mirae Asset Global Investments’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Mirae Asset Global Investments’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-197,854
Closed -$404K – 2642
2022
Q3 		$404K Sell
197,854
-10,651
-5% -$18.1K ﹤0.01% 2006
2022
Q2 		$321K Buy
+208,505
New +$815K ﹤0.01% 1958

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SGA
SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return

Mirae Asset Global Investments's PEAR Position: Q4 2022 in Review

Mirae Asset Global Investments sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q4 2022, closing a stake of 197,854 shares — an estimated $404K sold.

Mirae Asset Global Investments first reported a position in PEAR in Q2 2022 and held it in 2 quarters. The position peaked at $404K in Q3 2022. 64 funds tracked by Wall St. Rank hold PEAR as of Q4 2022.

  • Mirae Asset Global Investments reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
  • Mirae Asset Global Investments sold 197,854 Pear Therapeutics, Inc. Class A Common Stock shares in Q4 2022, an estimated $404K.
  • Mirae Asset Global Investments first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q2 2022 and held it in 2 quarters.
  • Mirae Asset Global Investments's Pear Therapeutics, Inc. Class A Common Stock position peaked at $404K in Q3 2022.
  • 64 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q4 2022.

Based on Mirae Asset Global Investments's 13F filing for Q4 2022, filed 9 Feb 2023.